TICKERNERD
Menu
NVCRNVCRHealthcare · Medical Devices

NVCR Stock Forecast: NovoCure Ltd. Price Predictions for 2026-2027

Last close, 14 Oct 2026
$14
−3.22% on the day

The 7 Wall Street analysts covering NovoCure Ltd. hold a median 12-month price target of $23 — +66.2% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 96 of 100 as at 14 Oct 2026 — among the strongest tenth. Here, the model and the Street point the same way.

Market cap
$1.7B
Ticker Nerd rank
96 / 100
Median analyst target
$23
Analysts covering
7
Revenue$183.6M+15.6% y/y
Operating income−$10.6M
Net income−$15.7M
Free cash flow$1.2M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−5.6%
1M
−14.7%
YTD
+7.0%
1Y
+5.1%
From 52W high
−30.8%
From 52W low
+38.0%
$10
$20
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

NVCR stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores NovoCure Ltd. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 14 Oct 2026
96 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Accruals
89
Revisions
87
Issuance
85
Growth
85
Quality
78
Value
68
Momentum
61
Size
38
Volatility
27

Accruals (89): Reported profit is backed by cash, and the company is not expanding recklessly.

Volatility (27): The share price moves around a lot.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

NVCR stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on NVCR, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$10$20$30$40$50Jan 26Apr 26Jul 26Oct 26NVCRHigh $52Median $23Low $17

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says7 analysts
4 Buy3 Hold0 Sell
Low $17Median $23High $52

The green dot is the last close — the median target sits +66.2% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
24 July 2026WedbushMaintainsNeutral$18 → $20
23 July 2026HC Wainwright & Co.MaintainsBuy$46 → $52
13 July 2026JP MorganReinstatesNeutral$17
18 June 2026HC Wainwright & Co.ReiteratesBuy—
4 May 2026Wells FargoMaintainsEqual-Weight—
1 May 2026Evercore ISI GroupMaintainsOutperform—
16 Apr 2026WedbushReiteratesNeutral—
26 Feb 2026HC Wainwright & Co.MaintainsBuy—
12 Feb 2026HC Wainwright & Co.MaintainsBuy—
15 Jan 2026WedbushReiteratesNeutral—
13 Jan 2026HC Wainwright & Co.MaintainsBuy—
30 Oct 2025HC Wainwright & Co.MaintainsBuy—
27 Oct 2025JP MorganMaintainsNeutral—
25 July 2025Wells FargoDowngradeEqual-Weight—
8 July 2025Ladenburg ThalmannInitiatesBuy—
27 June 2025Piper SandlerReiteratesOverweight—
23 Apr 2025Piper SandlerMaintainsOverweight—
16 Apr 2025WedbushMaintainsNeutral—
10 Apr 2025JP MorganMaintainsNeutral—
14 Jan 2025HC Wainwright & Co.ReiteratesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. NVCR appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

NVCR vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 14 Oct 2026, NovoCure Ltd. returned +5.1% against +17.5% for the S&P 500, dividends included.

NVCR vs S&P 500, last 12 monthsTotal return, rebased to 100
80100120140Jan 26Apr 26Jul 26Oct 26NVCRS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

NVCR analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
6
Analysts cutting
0
Fundamentals

NovoCure Ltd. (NVCR) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−11.7×

Cheaper than 94% of US stocks

Price / sales
2.4×

Cheaper than 47% of US stocks

Price / book
4.9×

Cheaper than 20% of US stocks

EV / EBITDA
−11.0×

Cheaper than 86% of US stocks

Growth & margins
Revenue growth (YoY)
15.6%

Higher than 63% of US stocks

Earnings growth (YoY)
15.6%

Higher than 54% of US stocks

Gross margin
77.6%

Higher than 89% of US stocks

Operating margin
−5.8%

Higher than 27% of US stocks

Net margin
−21.2%

Higher than 15% of US stocks

Returns & dividend
Return on equity
−43.2%

Higher than 23% of US stocks

Return on assets
−9.3%

Higher than 27% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

NovoCure Ltd. (NVCR) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • NovoCure Ltd. has a market value of $1.7B and an enterprise value of $1.5B.

  • Revenue in the twelve months to 30 June 2026: $699.2M. The latest quarter grew 15.6% year on year.

  • Net income over the same four quarters: −$148.6M, a −21.2% net margin.

  • Diluted earnings per share, trailing twelve months: $−1.30.

  • Free cash flow in the twelve months to 30 June 2026: −$25.4M, after $22.6M of capital spending.

  • Shares outstanding: 116.4M.

  • Trailing P/E: −11.7×; forward P/E: −17.7× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • NovoCure Ltd. employs 1,605 people — $436K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 13 Oct 2026

Data provided by Twelve Data

Peers

NVCR vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Devices
CompanyMarket capTKN rank
NVCRNovoCure Ltd.$1.7B
96
ATECAlphatec Holdings, Inc.$1.6B
74
ESTAEstablishment Labs Holdings, Inc.$1.7B
74
ALMRAlamar Biosciences, Inc. (California)$1.7B
4
CNMDCONMED Corp.$1.4B
95
INSPInspire Medical Systems, Inc.$1.9B
87
AXGNAxogen, Inc.$2.1B
80

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own NovoCure Ltd. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest NVCR news & analysis

Novocure: A Mispriced Cash-Generating Biotech With Upside Potential

Seeking Alpha · 13 Oct 2026positive

A Seeking Alpha article argues NovoCure is undervalued, citing 16% year-over-year revenue growth to $183.58 million, accelerating international sales and patient adoption, and valuation multiples below sector medians. It also points to the pipeline and anticipated Optune Mya launch as potential sources of upside.

Why it matters — NVCR watchers may find the article's discussion of revenue growth, product adoption, valuation, and pipeline relevant to the company's prospects.

Novocure's Optune Pax® Receives Approval in Japan for the Treatment of Unresectable Locally Advanced Pancreatic Cancer

Business Wire · 1 Oct 2026positive

Novocure announced that Japan's Ministry of Health, Labour and Welfare approved Optune Pax for the treatment of adult patients with unresectable locally advanced pancreatic cancer, to be used concomitantly with gemcitabine and nab-paclitaxel.

Why it matters — This regulatory approval expands Novocure's Optune Pax into a new indication in Japan, a significant market, potentially broadening the product's commercial reach.

Novocure to Report Third Quarter 2026 Financial Results

Business Wire · 1 Oct 2026neutral

Novocure announced it will report its third quarter 2026 financial results on October 29, 2026, before U.S. markets open. Management will host a conference call and webcast at 8:00 a.m. EDT that day to discuss results for the period ending September 30, 2026.

Why it matters — A Novocure watcher would care because the upcoming earnings report and conference call will provide the company's official financial results and management commentary for the quarter.

NovoCure Eyes Glioblastoma Growth, Cancer Launches and EBITDA Break-Even

MarketBeat · 18 Sept 2026neutral

NovoCure outlined its strategy at the Morgan Stanley Healthcare Conference for returning its glioblastoma franchise to growth, expanding its launches in pancreatic and lung cancer, and moving toward profitability. The company presented its plans for these initiatives during the conference.

Why it matters — A NovoCure watcher would care because the company laid out its forward roadmap covering its core glioblastoma business, new cancer indications, and its path toward EBITDA break-even.

NovoCure Limited (NVCR) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Seeking Alpha · 14 Sept 2026neutral

NovoCure Ltd. presented at the Morgan Stanley 24th Annual Global Healthcare Conference, and a transcript of its presentation was published by Seeking Alpha. The item records the company's participation in the conference.

Why it matters — A NVCR watcher would care because the conference presentation offers insight into how the company communicated its business to the investment community.

FAQ

Frequently asked questions about NVCR stock

What is the NVCR stock price forecast for 2026-2027?

The 7 Wall Street analysts covering NovoCure Ltd. have a median 12-month price target of $23, with estimates ranging from $17 to $52. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is NVCR stock a buy right now?

Of the 7 analysts covering NovoCure Ltd., 4 rate it a Buy, 3 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks NovoCure Ltd. 96 out of 100 across roughly 4,600 US stocks as at 14 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank NVCR?

As at 14 Oct 2026, NovoCure Ltd. ranks 96 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (89 of 100).

Will NVCR stock go up?

No one can know that. What the data says: the median 12-month target from 7 analysts implies +66.2% from the last close, and Ticker Nerd's factor model ranks NovoCure Ltd. 96 out of 100 as at 14 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the NVCR stock forecast for 2030?

No analyst covering NovoCure Ltd. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for NVCR are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $17 to $52 over the next 12 months.

How has NVCR stock performed over the past year?

NovoCure Ltd. returned +5.1% over the 12 months to 14 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does NovoCure Ltd. do?

NovoCure Ltd. is a global oncology company focused on developing and commercializing Tumor Treating Fields, a non-invasive cancer therapy that uses electric fields tuned to specific frequencies to disrupt solid tumor cell division.

What is the latest news on NVCR?

The most recent item we track (Seeking Alpha, 13 Oct 2026): "Novocure: A Mispriced Cash-Generating Biotech With Upside Potential". A Seeking Alpha article argues NovoCure is undervalued, citing 16% year-over-year revenue growth to $183.58 million, accelerating international sales and patient adoption, and valuation multiples below sector medians. It also points to the pipeline and anticipated Optune Mya launch as potential sources of upside.

Company

About NovoCure Ltd.

NovoCure Ltd. is a global oncology company focused on developing and commercializing Tumor Treating Fields, a non-invasive cancer therapy that uses electric fields tuned to specific frequencies to disrupt solid tumor cell division. Its current commercial portfolio includes Optune Gio for glioblastoma and Optune Lua for malignant pleural mesothelioma, with these therapies used alongside standard cancer treatments in approved markets. The company operates across the United States, Europe, Japan, Greater China, and other international regions, supporting patients through portable device-based treatment systems and related services. NovoCure Ltd. plays a specialized role in the cancer care market by offering a device-led treatment platform for difficult-to-treat solid tumors, combining medical technology, clinical support, and oncology-focused commercialization.

CEO Mr. Frank Leonard · 1,605 employees · Switzerland · https://www.novocure.com